Pneumococcal Vaccine Schedules
Phase 4
Recruiting
- Conditions
- pneumococci
- Registration Number
- PACTR202105646878477
- Lead Sponsor
- ondon School of Hygiene and Tropical Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40000
Inclusion Criteria
Resident in the study area
Exclusion Criteria
Intent to move out of the study area before 4 months of age.
Age greater than 9 months
Completed PCV schedule
Contraindication to PCV13 – severe hypersensitivity to a previous dose of PCV13
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of pneumococcal conjugate vaccines in inducing immune responses against Streptococcus pneumoniae serotypes?
How does a two-dose pneumococcal conjugate vaccine schedule compare to the standard three-dose regimen in preventing invasive pneumococcal disease in Gambian children?
Which biomarkers correlate with serotype-specific antibody responses to PCV in rural Gambian populations with high pneumococcal carriage rates?
What are the potential adverse event profiles of reduced-dose pneumococcal vaccination strategies in low-resource settings with co-circulating pathogens?
How does PCV schedule optimization impact herd immunity and serotype replacement dynamics in pneumococcal transmission in sub-Saharan Africa?